GarryMenzel
Operating Partner
Dr. Menzel is an Operating Partner at GHO Capital.
He was previously the founding President and Chief Executive Officer of TCR2 Therapeutics (Nasdaq:TCRR), leading the company from concept to clinical success with novel immunotherapies for solid tumors, before its strategic merger with Adaptimmune (Nasdaq:ADAP). He is also a founding board member of oncology company Black Diamond Therapeutics (Nasdaq:BDTX) and was appointed to the board of genetic disease company Stoke Therapeutics (Nasdaq:STOK). Prior to TCR2, he served in other operating roles as Chief Financial Officer of Fortune 500 company DaVita Healthcare (NYSE:DVA) and as Chief Operating Officer of microRNA company Regulus Therapeutics (Nasdaq:RGLS).
Dr. Menzel has also held advisory roles on Wall Street in building the global biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain where he worked with companies from a broad spectrum of industries to develop and implement strategies that create long-term value.
Dr. Menzel earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business and a Bachelor of Science degree, with honors, in Biochemistry from Imperial College.
He served in the British Armed Forces and engages in a number of adventure sports including high altitude mountaineering and scuba diving.